CL2013001975A1 - Dominio variable individual de inmunoglobulina anti-tgfbetarii; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica; y su uso para tratar una enfermedad asociada con la señalizacion de tgfbeta. - Google Patents

Dominio variable individual de inmunoglobulina anti-tgfbetarii; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica; y su uso para tratar una enfermedad asociada con la señalizacion de tgfbeta.

Info

Publication number: CL2013001975A1
Authority: CL; Chile
Prior art keywords: treat; vector; nucleic acid; pharmaceutical composition; production
Prior art date: 2011-01-06

Application number

CL2013001975A

Other languages

English (en)

Inventor

Susannah Karen Ford

Andrew Beaton

Caroline Dimech

Peter Franz Ettl

Ruth Mcadam

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-01-06

Filing date

2013-07-05

Publication date

2014-03-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45444622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013001975(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-07-05 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2014-03-07 Publication of CL2013001975A1 publication Critical patent/CL2013001975A1/es

Links

108060003951 Immunoglobulin Proteins 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
102000018358 immunoglobulin Human genes 0.000 title 1
150000007523 nucleic acids Chemical class 0.000 title 1
102000039446 nucleic acids Human genes 0.000 title 1
108020004707 nucleic acids Proteins 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
230000011664 signaling Effects 0.000 title 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)

CL2013001975A 2011-01-06 2013-07-05 Dominio variable individual de inmunoglobulina anti-tgfbetarii; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica; y su uso para tratar una enfermedad asociada con la señalizacion de tgfbeta. CL2013001975A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161430235P	2011-01-06	2011-01-06

Publications (1)

Publication Number	Publication Date
CL2013001975A1 true CL2013001975A1 (es)	2014-03-07

Family

ID=45444622

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013001975A CL2013001975A1 (es)	2011-01-06	2013-07-05	Dominio variable individual de inmunoglobulina anti-tgfbetarii; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica; y su uso para tratar una enfermedad asociada con la señalizacion de tgfbeta.

Country Status (22)

Country	Link
US (3)	US9150651B2 (es)
EP (1)	EP2661449B1 (es)
JP (2)	JP6062375B2 (es)
KR (1)	KR101886898B1 (es)
CN (1)	CN103443126B (es)
AU (1)	AU2016203609A1 (es)
BR (1)	BR112013016917A2 (es)
CA (1)	CA2823104A1 (es)
CL (1)	CL2013001975A1 (es)
CO (1)	CO6811807A2 (es)
CR (1)	CR20130376A (es)
DO (1)	DOP2013000162A (es)
EA (1)	EA201391012A1 (es)
ES (1)	ES2627299T3 (es)
IL (1)	IL227254A0 (es)
MA (1)	MA34820B1 (es)
MX (1)	MX2013007936A (es)
PE (1)	PE20140982A1 (es)
PH (1)	PH12013501397A1 (es)
SG (1)	SG191762A1 (es)
WO (1)	WO2012093125A1 (es)
ZA (1)	ZA201304726B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11644471B2 (en)	2010-09-30	2023-05-09	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2661449B1 (en) *	2011-01-06	2017-03-22	Glaxo Group Limited	Ligands that bind tgf-beta receptor ii
CN108659121A (zh) *	2011-06-23	2018-10-16	埃博灵克斯股份有限公司	用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术
MX374811B (es) *	2013-03-15	2025-03-06	Ac Immune Sa	Anticuerpos anti-tau y métodos de uso.
PL2992010T3 (pl)	2013-04-29	2021-08-23	F.Hoffmann-La Roche Ag	Modyfikowane asymetryczne przeciwciała wiążące receptor Fc i sposoby ich stosowania
CA2921805C (en)	2013-08-22	2023-03-07	Acceleron Pharma, Inc.	Tgf-beta receptor type ii variants and uses thereof
ES2902533T3 (es) *	2013-11-21	2022-03-28	Brigham & Womens Hospital Inc	Composiciones y métodos para tratar la hipertensión pulmonar
WO2015107025A1 (en) *	2014-01-15	2015-07-23	F. Hoffmann-La Roche Ag	Fc-region variants with modified fcrn-binding properties
CN110981957B (zh)	2014-01-15	2024-12-24	豪夫迈·罗氏有限公司	具有改善的蛋白A结合作用的Fc区变体
CA2956256A1 (en) *	2014-08-01	2016-02-04	The Brigham And Women's Hospital, Inc.	Methods and compositions relating to treatment of pulmonary arterial hypertension
IL302486A (en) *	2015-06-24	2023-06-01	Hoffmann La Roche	Antibodies against the transnephrine receptor with adapted affinity
CN108348578B (zh)	2015-08-04	2022-08-09	阿塞勒隆制药公司	用于治疗骨髓增生性病症的方法
US20190023809A1 (en) *	2015-09-03	2019-01-24	The Children's Mercy Hospital	Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
KR20250007038A (ko)	2015-10-02	2025-01-13	에프. 호프만-라 로슈 아게	이중특이성 항-인간 cd20/인간 트랜스페린 수용체 항체 및 사용 방법
WO2017080850A1 (en) *	2015-11-13	2017-05-18	Ablynx Nv	Improved serum albumin-binding immunoglobulin variable domains
JP2019510786A (ja)	2016-04-05	2019-04-18	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	免疫療法におけるＴＧＦβの阻害
LT3628049T (lt)	2017-05-04	2023-08-25	Acceleron Pharma Inc.	Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
GB201807693D0 (en) *	2018-05-11	2018-06-27	Autolus Ltd	Cell
WO2020009248A1 (ja) *	2018-07-04	2020-01-09	京都府公立大学法人	眼組織の線維化抑制用組成物
CN114173806A (zh) *	2019-07-26	2022-03-11	密歇根州立大学董事会	预防或治疗骨骼肌脂肪变性的方法
PH12022551527A1 (en)	2019-12-24	2024-01-29	Merus Nv	Tgf-beta-rii binding proteins
KR102314157B1 (ko) *	2020-01-10	2021-10-19	주식회사 뉴클릭스바이오	TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법
WO2022099090A1 (en) *	2020-11-06	2022-05-12	Xencor, Inc.	Heterodimeric antibodies that bind tgfbrii
JP2024506200A (ja)	2021-02-15	2024-02-09	武田薬品工業株式会社	細胞治療用組成物及びｔｇｆ－ｂシグナル伝達を調節する方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994026087A2 (en)	1993-05-14	1994-11-24	Connor Kim C O	Recombinant protein production and insect cell culture and process
IL127127A0 (en)	1998-11-18	1999-09-22	Peptor Ltd	Small functional units of antibody heavy chain variable regions
JP2001206899A (ja) *	1999-11-18	2001-07-31	Japan Tobacco Inc	ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US20050053973A1 (en)	2001-04-26	2005-03-10	Avidia Research Institute	Novel proteins with targeted binding
US20050089932A1 (en)	2001-04-26	2005-04-28	Avidia Research Institute	Novel proteins with targeted binding
WO2004058821A2 (en)	2002-12-27	2004-07-15	Domantis Limited	Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2003002609A2 (en)	2001-06-28	2003-01-09	Domantis Limited	Dual-specific ligand and its use
EP1572936A2 (en)	2002-03-05	2005-09-14	Eli Lilly And Company	Heterologous g-csf fusion proteins
US7696320B2 (en)	2004-08-24	2010-04-13	Domantis Limited	Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
EP1600459A3 (en)	2002-06-28	2005-12-07	Domantis Limited	Ligand
US20060002935A1 (en)	2002-06-28	2006-01-05	Domantis Limited	Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
EP2301967A3 (en)	2002-11-08	2011-07-13	Ablynx N.V.	Single domain antibodies for nasal administration
EP2357237A1 (en)	2003-05-14	2011-08-17	Domantis Limited	A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
CA2529819A1 (en)	2003-06-30	2004-09-23	Domantis Limited	Pegylated single domain antibodies
WO2005040229A2 (en)	2003-10-24	2005-05-06	Avidia, Inc.	Ldl receptor class a and egf domain monomers and multimers
JP5010923B2 (ja)	2004-02-09	2012-08-29	ヒューマンジノームサイエンシーズ，インコーポレイテッド	アルブミン融合蛋白質
PT1737962E (pt)	2004-03-24	2010-12-03	Domantis Ltd	Sequência líder universal gas1
GB0418651D0 (en)	2004-08-20	2004-09-22	Medical Res Council	Method
US20070012251A1 (en)	2005-07-07	2007-01-18	Martin Zucker	Seal arrangement with corrosion barrier and method
AU2007209202A1 (en)	2006-01-24	2007-08-02	Domantis Limited	Ligands that bind IL-4 and/or IL-13
GB0724331D0 (en)	2007-12-13	2008-01-23	Domantis Ltd	Compositions for pulmonary delivery
JO3096B1 (ar) *	2008-11-07	2017-03-15	Imclone Llc	الأجسام المضادة لمستقبل ii مضاد tgfb
US9109031B2 (en) *	2009-07-29	2015-08-18	Glaxo Group Limited	Ligands that bind TGF-β receptor RII
EP2496600A1 (en) *	2009-11-04	2012-09-12	Fabrus LLC	Methods for affinity maturation-based antibody optimization
EP2661449B1 (en) *	2011-01-06	2017-03-22	Glaxo Group Limited	Ligands that bind tgf-beta receptor ii

2012
- 2012-01-04 EP EP12700019.8A patent/EP2661449B1/en active Active
- 2012-01-04 MX MX2013007936A patent/MX2013007936A/es not_active Application Discontinuation
- 2012-01-04 ES ES12700019.8T patent/ES2627299T3/es active Active
- 2012-01-04 PE PE2013001516A patent/PE20140982A1/es not_active Application Discontinuation
- 2012-01-04 US US13/978,228 patent/US9150651B2/en not_active Expired - Fee Related
- 2012-01-04 JP JP2013547846A patent/JP6062375B2/ja not_active Expired - Fee Related
- 2012-01-04 WO PCT/EP2012/050061 patent/WO2012093125A1/en not_active Ceased
- 2012-01-04 KR KR1020137020615A patent/KR101886898B1/ko not_active Expired - Fee Related
- 2012-01-04 MA MA36101A patent/MA34820B1/fr unknown
- 2012-01-04 SG SG2013049663A patent/SG191762A1/en unknown
- 2012-01-04 BR BR112013016917A patent/BR112013016917A2/pt not_active Application Discontinuation
- 2012-01-04 PH PH1/2013/501397A patent/PH12013501397A1/en unknown
- 2012-01-04 CN CN201280012010.6A patent/CN103443126B/zh not_active Expired - Fee Related
- 2012-01-04 CA CA2823104A patent/CA2823104A1/en not_active Abandoned
- 2012-01-04 EA EA201391012A patent/EA201391012A1/ru unknown
2013
- 2013-06-25 ZA ZA2013/04726A patent/ZA201304726B/en unknown
- 2013-06-27 IL IL227254A patent/IL227254A0/en unknown
- 2013-07-03 DO DO2013000162A patent/DOP2013000162A/es unknown
- 2013-07-05 CL CL2013001975A patent/CL2013001975A1/es unknown
- 2013-07-16 CO CO13168686A patent/CO6811807A2/es unknown
- 2013-08-05 CR CR20130376A patent/CR20130376A/es unknown
2015
- 2015-09-02 US US14/843,250 patent/US9850307B2/en not_active Expired - Fee Related
2016
- 2016-05-31 AU AU2016203609A patent/AU2016203609A1/en not_active Abandoned
- 2016-10-20 JP JP2016205978A patent/JP6453289B2/ja not_active Expired - Fee Related
2017
- 2017-11-21 US US15/818,861 patent/US20180086835A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ZA201304726B (en)	2014-03-26
US9150651B2 (en)	2015-10-06
CA2823104A1 (en)	2012-07-12
JP6453289B2 (ja)	2019-01-16
JP6062375B2 (ja)	2017-01-18
US9850307B2 (en)	2017-12-26
ES2627299T3 (es)	2017-07-27
EA201391012A1 (ru)	2014-01-30
CO6811807A2 (es)	2013-12-16
JP2017051191A (ja)	2017-03-16
CN103443126B (zh)	2016-11-23
US20130302335A1 (en)	2013-11-14
BR112013016917A2 (pt)	2017-04-04
WO2012093125A1 (en)	2012-07-12
CR20130376A (es)	2013-11-29
KR101886898B1 (ko)	2018-08-08
DOP2013000162A (es)	2014-01-15
US20180086835A1 (en)	2018-03-29
PH12013501397A1 (en)	2013-08-28
EP2661449B1 (en)	2017-03-22
IL227254A0 (en)	2013-09-30
US20150361176A1 (en)	2015-12-17
AU2012204867A8 (en)	2016-03-24
SG191762A1 (en)	2013-08-30
JP2014504866A (ja)	2014-02-27
PE20140982A1 (es)	2014-08-22
AU2012204867B2 (en)	2016-03-10
CN103443126A (zh)	2013-12-11
KR20140036146A (ko)	2014-03-25
MX2013007936A (es)	2013-08-09
AU2016203609A1 (en)	2016-06-16
NZ612839A (en)	2014-09-26
MA34820B1 (fr)	2014-01-02
AU2012204867A1 (en)	2013-07-25
EP2661449A1 (en)	2013-11-13

Publication	Publication Date	Title
CL2013001975A1 (es)	2014-03-07	Dominio variable individual de inmunoglobulina anti-tgfbetarii; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica; y su uso para tratar una enfermedad asociada con la señalizacion de tgfbeta.
IL229539A0 (en)	2014-01-30	Hyaluronic acid-binding synthetic peptidoglycans, prepartion, and methods of use
CL2014000958A1 (es)	2014-08-29	Polipeptidos de anticuerpos que antagonizan cd4ol; acido nucleico que codifica dicho anticuerpo; vector y célula huesped que la comprenden; composicion farmacéutica; uso de dichos polipéptidos para tratar enfermedad inmunitaria.
CL2013000545A1 (es)	2014-09-26	Anticuerpo anti-ox40; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar cancer o una enfermedad autoinmune.
CL2014002903A1 (es)	2015-02-06	Composición geopolimérica de aluminosilicato; método de preparacion y sus usos.
CL2013003043A1 (es)	2014-06-20	Anticuerpos de un único dominio variable dab que se unen a cd40 humano; ácido nucleico que codifica dicho anticuerpo; vector y célula huésped que lo comprenden; composición farmacéutica; uso de dichos anticuerpos para tratar enfermedad inmune.
CL2015000757A1 (es)	2015-12-18	Una proteina
CL2014000183A1 (es)	2014-07-11	Formulación farmacéutica que contienen anticuerpos anti-pcsk9; metodo para preparar dicha formulación.
CL2013001625A1 (es)	2014-02-21	Proteina de union que se une especificamente a tnf-alfa; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar una enfermedad o trastorno asociado a tnf-alfa.
BR112013018877A2 (pt)	2016-10-04	composições farmacêuticas que compreendem anticorpos humanos para pcsk9
CO6920258A2 (es)	2014-04-10	Proteínas de función dual para tratar trastornos metabólicos
LT2776469T (lt)	2019-08-12	Antikūno molekulės, pasižyminčios specifiškumu žmogaus ox40
CL2015001157A1 (es)	2015-10-16	Composiciones y métodos para tratar proteinopatías.
BR112013031647A2 (pt)	2017-03-01	polissacarídeo péctico e método para produzir o mesmo
BR112014006324A2 (pt)	2016-06-07	método para tratar hcv
CL2013003336A1 (es)	2014-06-06	Anticuerpo anti-cgrp humano; acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica y diagnostica que lo comprende; y su uso terapéutico
BR112014031828A2 (pt)	2021-07-06	preparação, usos e formas sólidas de ácido obeticólico
BR112014002491A2 (pt)	2017-02-21	hormônio de crescimento de longa ação e métodos para produzir os mesmos
HUE053720T2 (hu)	2021-07-28	ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
CO7020865A2 (es)	2014-08-11	Microorganismos y métodos para producir alquenos
HRP20160854T1 (hr)	2016-09-23	Oligonukleotidi za izradu promjena u sekvenci ciljne rna molekule prisutne u živoj stanici
BR112014001855A2 (pt)	2017-02-21	construto e proteína aglutinantes ao antígeno, dímero, composição farmacêutica, sequência de polinucleotídeo, célula hospedeira e, método para produção do construto
BR112013014846A2 (pt)	2016-07-19	processo para produzir macarrão instantâneo
PT2489358E (pt)	2015-12-21	Produto de índigo naturalis extraído com um óleo, seu processo de preparação e utilização do mesmo
DK2768875T3 (da)	2020-12-21	Aminoplast-tværbinderresin-sammensætninger, proces til fremstilling deraf og fremgangsmåde til anvendelse